These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 20601886)

  • 1. Achondroplasia: pathogenesis and implications for future treatment.
    Laederich MB; Horton WA
    Curr Opin Pediatr; 2010 Aug; 22(4):516-23. PubMed ID: 20601886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGFR3 targeting strategies for achondroplasia.
    Laederich MB; Horton WA
    Expert Rev Mol Med; 2012 Jan; 14():e11. PubMed ID: 22559284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fibroblast growth factor receptor and achondroplasia].
    Tanaka H
    Clin Calcium; 2006 Nov; 16(11):1888-93. PubMed ID: 17079857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cytokines in bone diseases. FGF receptor signaling and achondroplasia/hypochondroplasia].
    Tanaka H
    Clin Calcium; 2010 Oct; 20(10):1490-6. PubMed ID: 20890030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia.
    Lorget F; Kaci N; Peng J; Benoist-Lasselin C; Mugniery E; Oppeneer T; Wendt DJ; Bell SM; Bullens S; Bunting S; Tsuruda LS; O'Neill CA; Di Rocco F; Munnich A; Legeai-Mallet L
    Am J Hum Genet; 2012 Dec; 91(6):1108-14. PubMed ID: 23200862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-Type Natriuretic Peptide Analog as Therapy for Achondroplasia.
    Legeai-Mallet L
    Endocr Dev; 2016; 30():98-105. PubMed ID: 26684019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Genetic basis for skeletal disease. CNP therapy for achondroplasia].
    Yasoda A; Nakao K
    Clin Calcium; 2010 Aug; 20(8):1212-8. PubMed ID: 20675932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTH has the potential to rescue disturbed bone growth in achondroplasia.
    Ueda K; Yamanaka Y; Harada D; Yamagami E; Tanaka H; Seino Y
    Bone; 2007 Jul; 41(1):13-8. PubMed ID: 17466614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice.
    Garcia S; Dirat B; Tognacci T; Rochet N; Mouska X; Bonnafous S; Patouraux S; Tran A; Gual P; Le Marchand-Brustel Y; Gennero I; Gouze E
    Sci Transl Med; 2013 Sep; 5(203):203ra124. PubMed ID: 24048522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotyping of the G1138A mutation of the FGFR3 gene in patients with achondroplasia using high-resolution melting analysis.
    Hung CC; Lee CN; Chang CH; Jong YJ; Chen CP; Hsieh WS; Su YN; Lin WL
    Clin Biochem; 2008 Feb; 41(3):162-6. PubMed ID: 18199430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed bone age due to a dual effect of FGFR3 mutation in Achondroplasia.
    Pannier S; Mugniery E; Jonquoy A; Benoist-Lasselin C; Odent T; Jais JP; Munnich A; Legeai-Mallet L
    Bone; 2010 Nov; 47(5):905-15. PubMed ID: 20673820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel FGFR3 mutations in exon 7 and implications for expanded screening of achondroplasia and hypochondroplasia: a response to Heuertz et al.
    Friez MJ; Wilson JA
    Eur J Hum Genet; 2008 Mar; 16(3):277-8. PubMed ID: 17895900
    [No Abstract]   [Full Text] [Related]  

  • 13. [Gly374Arg mutation in Fgfr3 causes achondroplasia in mice].
    Wang JM; Du XL; Li CL; Yin LJ; Chen B; Sun J; Su N; Zhao L; Song RH; Song WW; Chen L; Deng CX
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Dec; 21(6):537-41. PubMed ID: 15583977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The achondroplasia mutation does not alter the dimerization energetics of the fibroblast growth factor receptor 3 transmembrane domain.
    You M; Li E; Hristova K
    Biochemistry; 2006 May; 45(17):5551-6. PubMed ID: 16634636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meclozine promotes longitudinal skeletal growth in transgenic mice with achondroplasia carrying a gain-of-function mutation in the FGFR3 gene.
    Matsushita M; Hasegawa S; Kitoh H; Mori K; Ohkawara B; Yasoda A; Masuda A; Ishiguro N; Ohno K
    Endocrinology; 2015 Feb; 156(2):548-54. PubMed ID: 25456072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An improved tetra-primer PCR approach for the detection of the FGFR3 G380R mutation responsible for achondroplasia.
    Etlik O; Koksal V; Tugba Arican-Baris S; Baris I
    Mol Cell Probes; 2008 Apr; 22(2):71-5. PubMed ID: 17683901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vosoritide: First Approval.
    Duggan S
    Drugs; 2021 Nov; 81(17):2057-2062. PubMed ID: 34694597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3.
    Colvin JS; Bohne BA; Harding GW; McEwen DG; Ornitz DM
    Nat Genet; 1996 Apr; 12(4):390-7. PubMed ID: 8630492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of vosoritide in the treatment of achondroplasia.
    Paton DM
    Drugs Today (Barc); 2022 Sep; 58(9):451-456. PubMed ID: 36102905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway.
    Yasoda A; Komatsu Y; Chusho H; Miyazawa T; Ozasa A; Miura M; Kurihara T; Rogi T; Tanaka S; Suda M; Tamura N; Ogawa Y; Nakao K
    Nat Med; 2004 Jan; 10(1):80-6. PubMed ID: 14702637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.